PHOTO NEWS: Professor Bosede Afolabi and other stakeholders at the IVON close-out ceremony in Lagos

Phenomenal Published January 20, 2024

Last updated: 2024/01/20 at 10:11 AM

L-R: Director, Medical and Health Service, Kano State Ministry of Health, Dr Shehu Abdullahi; Deputy Director, Food and Drug Services Department, Essential Medicine list Division, Federal Ministry of Health, Yakubu Bulama; Director, Safe Motherhood Reproductive Health Division, FMoH, Dr Samuel Oyeniyi; Chief Investigator, IVON Trial/Director, Centre for Clinical Trials Research and Implementation Science, College of Medicine, University of Lagos, Prof Bosede Afolabi; Director of Africa Center of Excellence for Population Health and Policy, Bayero University Kano/Aminu Kano Teaching Hospital, Prof Hadiza Galadanci; Director, Specialty Hospitals, FMoH, Dr Aderemi Azeez; Deputy Provost elect, College of Medicine, University of Lagos, Prof Daniel Odebiyi; and Senior Program Officer, Health Global Development, Bill and Melinda Gates Foundation Nigeria, Dr Charity Chenge, during the IVON Trial close-out ceremony in Lagos… on Thursday.

About IVON: Trial Intravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women (IVON): a randomised controlled trial.

Anaemia in pregnancy (AIP) remains a critical global health problem especially in low- and middle-income countries (LMICs), affecting 46% of pregnant women in Africa and 49% in Asia. Iron deficiency anaemia (IDA) is the commonest cause of AIP, accounting for 50-75% of AIP.

Our aim is to compare the effectiveness of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating anaemia and IDA in pregnancy and to measure the acceptability, feasibility, fidelity (implementation outcomes) and the cost-effectiveness of intravenous iron among pregnant Nigerian women with moderate and severe anaemia, and IDA at 20–32 weeks’ gestation.

(From ivon.com)